Etudes académiques ouvertes aux inclusions

MOLECULE SPONSOR ACRONYME PHASE / TYPE STUDY TITLE LINK
NA CHU Lille PREDISTIM Cohorte Predictive Factors and Subthalamic Stimulation in Parkinson's Disease 
L-threoDops CHU Toulouse DOPS-AMS IV Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA 
Défériprone CHU Lille FAIRPARKII II Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease 
Buspirone AP-HP Créteil BUSPARK III Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease 
NA CHU Clermont-Ferrand MPI-R2* NA One-year Follow-up of Iron in Basal Ganglia - R2*: a Biomarker of Parkinson's Disease Progression? 
Apomorphine CHU Rennes EARLY-PUMP III Apomorphine Pump in Early Stage of Parkinson's Disease 
Oxycodone / levodopa CHU Toulouse OXYDOPA II / III Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease 
Botox CHU Clermont-Ferrand Btx-HT III Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor 
Rivastigmine AP- HM RIVA-PSP III Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy 
NA CHU Strasbourg PROBA-PD Cohort

Prognosis of Behavioral Addiction in Parkinson's DiseasePrognosis of Behavioral Addiction in Parkinson's Disease

Lixisenatide CHU Toulouse LIXIPARK II

Multicenter, randomised, placebo-controlled, double-blinded, parallel arm proof-of concept trial of Lixisenatide in patients with early Parkinson’s disease

NA AP-HP DATACOMT Cohort

Compensation Mechanisms in Parkinson's Disease

NA Hospices civils de Lyon WILSTIM Cohort WILson STIMulation - Deep Brain Stimulation
NA CHU toulouse 3PDQ Scale validation Conception and validation of a diagnostic questionnaire for primary Parkinsonian pain: the "Primary Parkinsonian Pain Questionnaire 3PDQ"
Français